Theratechnologies Common Stock Net 2011-2025 | THTX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Theratechnologies common stock net from 2011 to 2025. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Theratechnologies common stock net from 2011 to 2025. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$228.1B
Amgen (AMGN)	$155.2B
Gilead Sciences (GILD)	$148.2B
Vertex Pharmaceuticals (VRTX)	$94B
Bristol Myers Squibb (BMY)	$93.5B
CSL (CSLLY)	$82.7B
GSK (GSK)	$77.1B
Regeneron Pharmaceuticals (REGN)	$59.7B
Alnylam Pharmaceuticals (ALNY)	$57.5B
Argenex SE (ARGX)	$40.5B
BioNTech SE (BNTX)	$26.8B
Insmed (INSM)	$23.2B
Royalty Pharma (RPRX)	$21.1B
Biogen (BIIB)	$19.2B
Incyte (INCY)	$15.3B
Illumina (ILMN)	$14.5B
Genmab (GNMSF)	$14.3B
Genmab (GMAB)	$13.7B
Ascendis Pharma (ASND)	$11.7B
BioMarin Pharmaceutical (BMRN)	$11B
QIAGEN (QGEN)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Moderna (MRNA)	$10.2B
Exelixis (EXEL)	$10.2B
Verona Pharma American Depositary Share (VRNA)	$9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$7.9B
Roivant Sciences (ROIV)	$7.8B
Exact Sciences (EXAS)	$7.8B
Halozyme Therapeutics (HALO)	$7.8B